Dr. John Cush RheumNow
3 years 8 months ago
Treatment Considerations in Axial Spondyloarthritis
https://t.co/GRQfk4B4QN https://t.co/xX5AYAD90c
Dr. John Cush RheumNow
3 years 8 months ago
2022 Memorium
Sadly, too many of our rheumatology colleagues passed on in 2022. Here is an (incomplete) list of notable brethren, mentors, do-gooders and great rheumatologists.
https://t.co/wtr4ablgUm https://t.co/xPpgnrEQWz
Dr. John Cush RheumNow
3 years 8 months ago
2022 Rheumatology Year in Review
Dr. Jack Cush reviews the best of 2022 in Rheumatology - highlights on new drug indications, breakthrough lupus therapies, new biosimilars and the multivitamin letdown.
https://t.co/6r6W95moyr https://t.co/PNlMDId7qX
Dr. John Cush RheumNow
3 years 8 months ago
AutoAb analysis of 140 systemic sclerosis shows low sensitivity (<33%), high specificity (>88%). Scl-70+ signif assoc w sine scleroderma, digital ulcers, Raynauds as 1st onset sign. SSc-ILD more common Scl-70 and PAH with CENP A/B Abs https://t.co/1zvkte4drJ https://t.co/FaSmshUvhY
Dr. John Cush RheumNow
3 years 8 months ago
PsABiostudy followed PsA pts starting TNFi vs ustekinumab x12 mos showing equivalent durability at 1 yr (72% vs 71%). cDAPSA LDA was seen in 56% UST vs 67% TNFi (similar for MDA (34% vs 43%) https://t.co/briK7itZtL https://t.co/Rq1SXA7s1s
Dr. John Cush RheumNow
3 years 8 months ago
UK Database 1,955 breakthrough COVID-19 infxs in 54,576 #gout pts compared to 52,468 w/o gout saw more in gout (adj HR 1.24), also w/ more #COVID hospitalizations (adj HR 1.30) & death (1.36), more so in women. Same for unvaccinated https://t.co/596KvupZxi https://t.co/BJJguQBdin
Certain T cells can secrete cytokines that are normally part of the innate immune system, as researchers from the Leibniz Institute for Natural Product Research and Infection Biology (Leibniz-HKI) and an international research team discovered. They have thus revealed several previously unknown properties of these immune cells that are relevant regarding both autoimmune diseases as well as fighting fungal infections.
Tofacitinib (Xeljanz) appeared highly effective against polymyalgia rheumatica (PMR) in a small single-arm trial, researchers said, suggesting another potential alternative to long-term corticosteroids.
Dr. John Cush RheumNow
3 years 8 months ago
Autoimmune Dz may be assoc w/ new-onset Atrial Fibrillation, esp in women. Population-based UK Biobank found significant increases for AFib in Rheumatic fever w/o CVD (HR 1.47), Crohn’ (1.23), UC(1.17), RA (1.39), PAN (1.82), SLE (1.82), PSS (2.32) https://t.co/rpIiztUfg9 https://t.co/FWmLiZ6x1S
Dr. John Cush RheumNow
3 years 8 months ago
Abbvie has forcasted sales sales revenues in 2025 for Skyrizi and Rinvoq to be more than $17.5 billion. This year Humira goes off patent. https://t.co/YrIdkEhL7M https://t.co/MuuVYkyXRv
Dr. John Cush RheumNow
3 years 8 months ago
Status of #RA; an Egyptian College of Rheumatology study of 10,364 pts from 26 centers.
Mean age 45 yrs, Dz duration 6.4 yrs, onset age 38. (F:M 5.4:1)
DAS28 was 4.4 & HAQ 0.95
RF+ 74%, CCP+ 67%
Rx use: MTX 78%, HCQ 74%, steroids 71%, Biologics 11.6% https://t.co/19omwKqAQl https://t.co/m04QabOwgZ
Dr. John Cush RheumNow
3 years 8 months ago
Evidence based Latin American Guidelines of clinical practice on prevention, diagnosis, management and treatment of glucocorticoid induced osteoporosis. A 2022 update https://t.co/2lwWc8PqIw https://t.co/uYdYwJofwJ
Dr. John Cush RheumNow
3 years 8 months ago
Network meta-analysis of 152 RCTs (17431 pts) comparing efficacy of exercise therapy, NSAIDs, Tylenol for knee or hip osteoarthritis: Found all 3 equivalent at 4 wk, 8 wk and 24 wks. https://t.co/rKck2AacL4 https://t.co/YEAMh9UxTs
The American College of Physicians (ACP) has updated its 2017 recommendations on pharmacologic treatment of primary osteoporosis or low bone mass to prevent fractures in adults. The full document and guideline can be found in the Annals of Internal Medicine. This guideline is the result of an expert panel literature review and GRADE evaluations.
